After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
The bond market has entered a financial twilight zone, and at this point, there doesn't seem to be a smooth way out.Market Insiderread more
Trump said he has "been thinking about payroll taxes for a long time" — and he cautioned that "whether or not we do something now, it's not being done because of recession."Politicsread more
Secretary of State Mike Pompeo privately told business executives and free traders that the trade war could end by the 2020 election and that hurdles to an immediate agreement...2020 Electionsread more
Market bull Jeff Saut told CNBC on Tuesday that the lows are in and the market is headed "much higher."Marketsread more
The company's stock seesawed after the markets closed Tuesday, initially swinging up by 4% before falling by about 2%.Retailread more
President Donald Trump believes he has quite the bargaining chip with the European Union.Marketsread more
Some Apple employees have become disillusioned with the group's culture, where some have thrived while others feel sidelined.Technologyread more
The United States does not have a defense against hypersonic weapons, which can travel at least five times the speed of sound, or a little more than a mile per second....Defenseread more
President Donald Trump renewed calls Tuesday to readmit Russia to the G-7 ahead of the group's summit in Biarritz, France, this weekend.Politicsread more
Biden has shown staying power at the top of a jammed Democratic field even as polling numbers for Sanders, Warren and Harris wax and wane.2020 Electionsread more
The CEO of AstraZeneca told CNBC that the U.K. pharmaceutical giant was big enough to thrive alone, but would still consider any takeover bids that fully reflected its value.
"We have the critical mass... we have the scale that is required to succeed," Pascal Soriot told CNBC on Tuesday, after a hearing with U.K. lawmakers to discuss Pfizer's ongoing efforts to acquire AstraZeneca.
"We have a very focused strategy, which is science-led. We have made enormous progress in the past 18 months in improving our pipeline… We can create value by progressing these projects and we believe with our standalone strategy we will create great value for shareholders."
However, Soirot said that AstraZeneca's board had a "fiduciary responsibility" to consider any reasonably priced takeover bid.
"We of course consider any offer that is made to us that we feel reflects the value of the company," he told CNBC.
This came after Pfizer chief executive, Ian Read, suggested at the AstraZeneca-Pfizer hearing that he would consider raising the latest $106 billion offer. This was Pfizer's second offer, worth £50 ($84.20) a share, and AstraZeneca rejected it earlier this month.
At the hearing, Read was grilled on his commitment to U.K. research spending and jobs in the event of a takeover. This came as Read was grilled by the politicians on his commitment to U.K. research spending and jobs.
According to Reuters, Scottish-born Read pledged to keep a fifth of research jobs in the U.K., but said he could not commit to maintaining a specific R&D budget there. He also said that Pfizer had not ruled out a hostile bid.
The questions were pertinent given AstraZeneca's strong presence in the U.K. in terms of employment and research facilities – it is building a £330 million research and development center in Cambridge, which will house a 2,000-strong workforce by 2016.
"I think what is important to keep in mind, is that we have a strong history in this country… we have a very strong presence," Soriot told CNBC.
"We are making an enormous investment in Cambridge at a time when the company is… suddenly going through a transition and challenging times."
Soriot added that Pfizer's ongoing acquisition efforts were a "distraction" from AstraZeneca's day-to-day work. He advised AstraZeneca employees to stay focused on their usual work.
"Stay focused on the task at hand. Patients are waiting for products… Stay focused on your work and progress the projects you are working on as quickly as you can," he said in his CNBC interview.